icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
p8uLaD2tXfkM27cQ
Listen
